Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run
08:25am, Sunday, 02'nd Jun 2024
The vast majority of patients using GLP-1 agonists such as Ozempic and Wegovy are being treated for diabetes or chronic weight management. GLP-1 medications are believed to have further applications,
Nutritional needs for users of GLP-1 drugs are 'shifting', Nestle CEO says
11:35am, Thursday, 30'th May 2024
Nestle CEO Mark Schneider discusses the impact of GLP-1 drugs on the food industry and the company's products that are tailored to users of the drugs.
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
11:32am, Tuesday, 28'th May 2024
As weight loss drugs are gaining popularity a new way to invest in the companies behind these products has launched with the Roundhill GLP 1 And Weight Loss ETF (NASDAQ:OZEM). Let's get into everythin
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its le
How digital health companies are capitalizing on the GLP-1 boom
09:00am, Saturday, 25'th May 2024
Some analysts estimate that anti-obesity medications could grow into a $100 billion industry by the end of the decade. Companies including Calibrate, Ro and WeightWatchers are looking to capitalize on
Company announcement – No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Mean w
Victory Square Company Announces Access to Tirzepatide and GLP-1 Injections to its Weight Loss Portfolio
07:45am, Thursday, 23'rd May 2024
Hydreight Technologies announced the addition of Tirzepatide to its weight loss portfolio which also includes GLP-1 injections, giving patients a cost-effective way to access safe, high quality diabet
Amid ‘Ozempic babies' questions, women account for more than 75% of young adults taking GLP-1 drugs, study finds
11:04am, Wednesday, 22'nd May 2024
More than three out of four young adults prescribed GLP-1 drugs last year were women, new research shows, raising questions about how societal views of women's weight may influence use of these medica
Hims & Hers Health stock price nears record high on news that it will offer GLP-1 weight-loss drugs amid shortages
10:51am, Tuesday, 21'st May 2024
Hims & Hers Health got a shot in the arm this week that sent its share prices to near all-time highs.
Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)
09:00am, Tuesday, 21'st May 2024
OZEM provides exposure to the rapidly growing weight loss management market, which is expected to reach $100 billion by 2030. NEW YORK , May 21, 2024 /PRNewswire/ -- Roundhill Investments, an ETF spon
MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications
08:30am, Tuesday, 21'st May 2024
Formulations to be marketed as “Slim” and “Trim” as an Oral Dissolvable Tablet (ODT) Dallas, TX, May 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “C
Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
08:15am, Tuesday, 21'st May 2024
Hims & Hers Health's share price increased by over 25% after announcing the availability of compounded GLP-1 agonist weight loss drugs at a fraction of the price of branded drugs. The company aims to
Nestle to launch Vital Pursuit frozen-food brand targeting GLP-1 users
07:41am, Tuesday, 21'st May 2024
Nestle's Vital Pursuit brand's initial lineup of 12 items will include frozen bowls with whole grains or protein pasta, sandwich melts and pizzas.
Dr. Craig Primack talks Hims & Hers launching its own GLP-1 offering as demand rises
06:43pm, Monday, 20'th May 2024
Dr. Craig Primack, Hims & Hers SVP of Weight Management, joins 'Closing Bell Overtime' to talk the company offering a GLP-1 drug through its platform.
BGL Announces the Recapitalization of Musser Biomass and Wood Products by Watermill Group
05:17pm, Monday, 20'th May 2024
Musser is a provider of ESG-certified engineered biomass wood fiber products CLEVELAND, May 20, 2024 /PRNewswire/ -- Brown Gibbons Lang & Company (BGL) is pleased to announce the recapitalization of M
